معرفی
Xian Chen, PhD, is an Associate Professor of Biochemistry and Biophysics at the University of North Carolina at Chapel Hill School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center. He serves as the Faculty Director for the Quantitative Proteomics Center for Disease Markers and Director of Technology Development in the UNC Proteomics Center. His research program focuses on developing and applying cutting-edge proteomics technologies to investigate molecular pathways of human diseases including cancer, immune disorders, and inflammation-associated conditions.
Dr. Chen's research interests span proteomics, mass spectrometry, systems biology, and molecular mechanisms of disease pathogenesis. His lab pioneered the development of amino acid-coded mass tagging (AACT), also known as SILAC, which has unique strengths for comparative analysis of protein-protein interactions and post-translational modifications. His current work explores signaling and epigenetic regulatory pathways underlying how tumor cells escape immune surveillance, with particular focus on Toll-like receptor (TLR)-mediated pathways and DNA damage response pathways. His research aims to derive novel, precise disease markers for early diagnosis and therapeutic intervention.
Analysis of Dr. Chen's recent publications (2023-2025) reveals a strong focus on targeted protein degradation technologies, particularly PROTACs (Proteolysis Targeting Chimeras) and related molecular approaches. His work spans multiple disease areas including cancer, neurodegenerative disorders, and viral pathogenesis, demonstrating the versatility of his proteomics expertise. The publications show consistent collaboration with researchers across various disciplines, highlighting his integrative approach to biomedical research.
Dr. Chen maintains an active research program with numerous ongoing projects in proteomics technology development and application to disease mechanisms. His recent work demonstrates significant contributions to the emerging field of targeted protein degradation, with multiple publications in high-impact journals describing novel approaches to modulate protein levels for therapeutic purposes.
